a 2015

13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.

KOTAŠKOVÁ, Jana; Jitka MALČÍKOVÁ; Eva DIVÍŠKOVÁ; Šárka PAVLOVÁ; Soňa MEJSTŘÍKOVÁ et. al.

Basic information

Original name

13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.

Name (in English)

13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.

Authors

Edition

20th Congress of the European Hematology Association in Haematologica, 2015

Other information

Type of outcome

Conference abstract

Field of Study

30200 3.2 Clinical medicine

Confidentiality degree

is not subject to a state or trade secret

Organization unit

Central European Institute of Technology

Tags

International impact, Reviewed
Changed: 12/10/2015 20:15, Bc. Kateřina Kolesová

Links

ED1.1.00/02.0068, research and development project
Name: CEITEC - central european institute of technology
NT13493, research and development project
Name: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
NT13519, research and development project
Name: Časná identifikace CLL pacientů s dosud nevyselektovanými mutacemi v proteinu p53
306242, interní kód MU
Name: NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: European Union, Cooperation
7E13008, research and development project
Name: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: Ministry of Education, Youth and Sports of the CR